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Abstract
Background: Genome-wide association studies have identified more than 30 Alzheimer’s disease (AD) risk genes, although
the detailed mechanism through which all these genes are associated with AD pathogenesis remains unknown. We
comprehensively evaluate the roles of the variants in top 30 non-APOE AD risk genes, based on whether these variants were
associated with altered mRNA transcript levels, as well as brain amyloidosis, tauopathy, and neurodegeneration.
Methods: Human brain gene expression data were obtained from the UK Brain Expression Consortium (UKBEC), while other
data used in our study were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. We examined the
association of AD risk allele carrier status with the levels of gene expression in blood and brain regions and tested the
association with brain amyloidosis, tauopathy, and neurodegeneration at baseline, using a multivariable linear regression
model. Next, we analyzed the longitudinal effects of these variants on the change rates of pathology using a mixed effect
model.
Results: Altogether, 27 variants were detected to be associated with the altered expression of 21 nearby genes in blood and
brain regions. Eleven variants (especially novel variants in ADAM10, IGHV1-68, and SLC24A4/RIN3) were associated with brain
amyloidosis, 7 variants (especially in INPP5D, PTK2B) with brain tauopathy, and 8 variants (especially in ECHDC3, HS3ST1) with
brain neurodegeneration. Variants in ADAMTS1, BZRAP1-AS1, CELF1, CD2AP, and SLC24A4/RIN3 participated in more than one
cerebral pathological process.
Conclusions: Genetic variants might play functional roles and suggest potential mechanisms in AD pathogenesis, which
opens doors to uncover novel targets for AD treatment.
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Background
Alzheimer’s disease (AD) is highly heritable, with late-
onset AD (LOAD) showing heritability of 58–79% [1].
Previous large-scale genome-wide association studies
(GWASs) have discovered more than 20 AD gene
variants that confer risk for LOAD [2–7]. APOE is still
the strongest genetic risk factor for LOAD, responsible
for a 3- to 15-fold increase in risk [8]. Yet these con-
firmed variants only account for a small portion of dis-
ease heritability. In the search for additional LOAD risk
variants, recent GWAS meta-analyses [9–11] identified
totally more than 30 AD risk genes. The identification of
these novel gene variants might provide valuable insights
into the molecular mechanisms with important roles in
AD pathogenesis.
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Although most of the non-APOE AD-associated gen-
etic variants described to date are located in intronic or
noncoding regions, these variants still could affect the
nearby gene expression and exert protective or disease-
inducing effects [12, 13]. In addition, AD develops fol-
lowing a long pre-clinical phase with abnormal neuro-
pathological biomarkers [14]. Recently, the National
Institute on Aging and Alzheimer’s Association (NIA-
AA) published an updated research framework [15] that
provides a flexible platform to generate or test hypoth-
eses concerning different pathologic processes of AD,
which defines AD by neuropathological biomarkers in
three categories: amyloidosis [A] biomarkers, particularly
cortical amyloid-PET ligand binding or low CSF Aβ42;
tauopathy [T] biomarkers, particularly elevated CSF
phosphorylated tau (pTau) or cortical tau-PET ligand
binding; and neurodegeneration [N] biomarkers, particu-
larly elevated CSF total tau (tTau), diminished 18F-fluor-
odeoxyglucose (FDG)-PET, or brain structural atrophy
on MRI.
Many of the early identified AD variants have been as-
sociated with expression levels of their nearby genes and
implicated in brain amyloidosis and neurodegeneration
[12, 16, 17]. Relatively, fewer studies have reported asso-
ciations of these top AD risk gene variants with brain
tauopathy [18–20], and most of these studies focused on
a single variant, or a few variants. More importantly, the
precise disease-associated mechanisms of the novel gen-
etic variants identified in the recent GWAS meta-
analysis remain unknown. Here, we report a comprehen-
sive analysis of the associations of the variants in the top
30 non-APOE AD risk genes from current large-scale
GWAS studies of the transcript expression levels, and
the pathological processes of brain amyloidosis, tauopa-
thy, and neurodegeneration, using the baseline and
follow-up data from AD-related CSF, PET, and MRI
measures. Understanding the mechanisms by which
these variants contribute to AD risk will lead to a better
understanding of the disease-associated mechanisms and
help uncover novel therapeutic avenues.
Methods
Study design and participants
Human brain gene expression data were obtained from
Braineac dataset, UK Brain Expression Consortium
(UKBEC), and included 10 brain regions from 134 neu-
ropathologically normal individuals of European descent.
The 10 brain regions were the cerebellar cortex (CRBL),
frontal cortex (FCTX), hippocampus (HIPP), medulla
(MEDU), occipital cortex (OCTX), putamen (PUTM),
substantia nigra (SNIG), temporal cortex (TCTX), thal-
amus (THAL), and intralobular white matter (WHMT).
In the Braineac dataset, Affymetrix GeneChip Human
exon 1.0ST arrays were used to measure the gene
expression in transcript levels. Detailed information on
these methods is described in the Braineac database
[21]. Genomic DNA for individuals from UKBEC was
extracted from sub-dissected samples (100–200mg) of
human post-mortem brain tissue using Gentra Puregene
Kit (Qiagen, UK). Samples from every individual were
run on the genotype chip (the Illumina Infinium
Omni1-Quad BeadChip). The BeadChips were scanned
using an iScan (Illumina, USA) with an AutoLoader
(Illumina, USA). GenomeStudio v.1.8.X (Illumina, USA)
was used for analyzing the data and generating SNP
calls. All other data used in this study were obtained
from Alzheimer’s Disease Neuroimaging Initiative
(ADNI) database (http://adni.loni.usc.edu). ADNI was
launched in 2003 as a public-private partnership, led by
Principal Investigator Michael W. Weiner, MD, VA
Medical Center and University of California-San Fran-
cisco. Our analyses included all individuals with diag-
nosed AD, mild cognitive impairment (MCI), and
normal cognition (NC), with clinical information,
GWAS data, and gene expression data from peripheral
blood (Affymetrix Human Genome U219 Array plat-
form), or longitudinal AD-related CSF, PET, and MRI
data. Furthermore, we selected only non-Hispanic white
individuals to avoid population stratification effects
which can lead to spurious findings. In total, 1183 indi-
viduals at baseline were included in our study (Table 1).
Among them, 739 individuals had gene expression data
(Additional file 1: Figure S1).
Gene variant selection and imputation
The ADNI-1, ADNI-2, and ADNI–Grand Opportunity
(GO) participants were genotyped according to the man-
ufacturer’s protocol. We focused on well-established AD
risk genes identified in AD GWASs available to date
(Additional file 1: Table S1), which yielded a total of 68
variants. Missing genotypes were imputed using the Bea-
gle software with the HapMap GRCh37 as a reference.
Among them, 19 of our genes were represented by more
than one variant. We performed linkage disequilibrium
(LD) analyses followed by Cohen kappa (κ) statistics.
When choosing between 2 variants with significant over-
lap (high r2 and high κ), we retained the variant with the
smallest amount of missing data. Our final number of
non-APOE AD variants was thus reduced to 42 (Add-
itional file 1: Table S2). More detailed information is de-
scribed in Additional file 1 .
CSF measurements
CSF Aβ42 and pTau were measured at the ADNI Bio-
marker Core Laboratory (University of Pennsylvania)
using the multiplex xMAP Luminex platform (Luminex
Corp, Austin, TX) with Innogenetics (INNO-BIA Alz-
Bio3; Ghent, Belgium; for research use only reagents)
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immunoassay kit-based reagents. All CSF biomarker as-
says were performed in duplicate and averaged.
AV45-PET/AV1415-PET data acquisition and analyses
A detailed description of PET image acquisition and
processing can be found at http://adni.loni.usc.edu/
datasamples/pet/. The AV45-PET (amyloid-PET) and
AV1415-PET (tau-PET) standardized uptake value ratios
(SUVRs) were formed by normalizing composite multi-
region target regions of interest (ROIs) to the cerebellar
crus gray matter. The amyloid-PET target meta-ROI in-
cluded the frontal, anterior cingulate, precuneus, and
parietal cortex [22]. The tau-PET target meta-ROI used
in the primary analysis included the amygdala, entorhi-
nal cortex, fusiform, parahippocampal, and inferior tem-
poral and middle temporal gyri [23].
FDG-PET data acquisition and analyses
The cerebral metabolic rate for glucose (CMRgl) data on
FDG-PET was downloaded from the ADNI dataset.
Mean FDG uptake was averaged from 5 meta-ROIs in-
cluding the right and left angular gyri, right and left in-
ferior temporal regions, and bilateral posterior cingulate.
PET images were spatially normalized in Statistical Para-
metric Mapping (SPM) to the MNI PET template. We
intensity-normalized each meta-ROI mean by dividing it
by the pons/vermis reference region mean.
Structural MRI data
Hippocampal volume (HV) and estimated intracranial
volume (eICV) were performed from T1-weighted MRI
acquired with a Siemens Trio 3.0 T or 1.5 T scanner. Re-
gional volume estimates were processed using the Free-
surfer software (https://surfer.nmr.mgh.harvard.edu). HV
was adjusted for eICV using the following equation: Ad-
justed HV (HVa) = Raw HV – b (eICV – Mean eICV),
where b is the regression coefficient when HV is
regressed against eICV.
Statistical analyses
Clinical and demographic characteristics for each variant
were compared using t tests or χ2 tests with 2-sided P
values, as appropriate. First, a multivariable linear regres-
sion model was used to analyze the association of AD
risk allele carrier status with the gene expression levels,
using the genes that have been annotated to those vari-
ants by GWAS. Age and gender as covariates were in-
cluded in the model and tested for statistical
significance. A multivariable linear regression model was
also used to analyze the association of AD risk allele car-
rier status with brain amyloidosis, tauopathy, and neuro-
degeneration, based on AD-related CSF, PET, and MRI
data at baseline. Age, gender, educational level, APOEε4
genotype, and diagnosis were included as covariates.
Then, we analyzed the longitudinal effects of these vari-
ants on the change rates of pathologically characteristic
data above, using a multivariable linear mixed effect
model with fixed effects of time (year) from baseline, AD
risk allele carrier status, and interaction between time
from baseline and AD risk allele carrier status. The
model included random slope and intercept terms for
each participant with age, gender, educational level,
APOEε4 genotype, and diagnosis as covariates. All statis-
tical analyses were conducted using R statistical soft-
ware. We defined associations with false discovery rate
(FDR)-adjusted P values < 0.05 as statistically significant
using the Benjamini-Hochberg procedure.
Results
Association of variants with gene expression in the blood
The associations between AD risk allele carrier status
and gene expression in the blood are shown in Add-
itional file 1: Table S3. Figure 1 shows those associated
Table 1 Demographic characteristics of study subjects in ADNI
Characteristics NC (N = 339) MCI (N = 639) AD (N = 205)
Age (mean years ± SD) 75.15 ± 5.35 73.44 ± 7.52 75.53 ± 7.81
Gender (n (%)) –
Male 177 (52.21) 389 (60.88) 117 (57.07)
Female 162 (47.79) 250 (39.12) 88 (42.93)
Education (mean years ± SD) 16.30 ± 2.68 15.89 ± 2.84 15.03 ± 2.96
APOE status (n (%))
APOE ε2/ε2,ε2/ε3,ε3/ε3 247 (72.86) 325 (50.86) 66 (32.20)
APOE ε2/ε4,ε3/ε4 83 (24.48) 250 (39.12) 101 (49.27)
APOE ε4/ε4 9 (2.65) 64 (10.02) 38 (18.54)
MMSE (means ± SD) 29.07 ± 1.12 27.60 ± 1.78 23.29 ± 2.03
Abbreviations: AD Alzheimer’s disease, ADNI Alzheimer’s Disease Neuroimaging Initiative, MCI mild cognitive impairment, MMSE Mini-Mental State Exam scores, N
number, NC normal cognition, SD standard deviation
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variants that reached FDR-adjusted significance level. In
total, 15 variants were detected to be associated with the
altered expression in blood of 10 nearby genes. The
minor alleles of 5 variants in CR1, ECHDC3, MS4A6A,
and NME8 were associated with decreased expressions,
while the other 10 variants in BIN1, EPHA1, HLA-DRB1,
PTK2B, SLC24A4/RIN3, and ZCWPW1 associated with
increased expressions.
Association of variants with gene expression in the brain
The associations between AD risk allele carrier status
and brain gene expression are shown in Add-
itional file 1: Table S4. Figure 1 shows the signifi-
cantly associated variants in 10 different brain
regions. In total, 18 variants were detected to be asso-
ciated with the altered expression of 15 nearby genes
in specific brain regions. Especially in AD-related
TCTX, HIPP, and FCTX regions, the minor alleles of
rs11136000 in CLU and rs6701713 in CR1 were asso-
ciated with increased expressions of CLU and CR1.
The minor alleles of rs2526378 in BZRAP1-AS1 and
rs12590654 in SLC24A4/RIN3 were also associated
with increased expression especially in TCTX/FCTX
and FCTX, respectively, while the minor allele of
rs3865444 in CD33 was associated with decreased ex-
pression in TCTX (Additional file 1: Figure S2).
Association of variants with brain amyloidosis
We tested for associations of AD risk allele carrier status
with brain amyloidosis, based on CSF Aβ42 or amyloid-
PET data at baseline and follow-up. Our results indicate
that ABCA7 rs3752246 was significantly associated with
CSF Aβ42 levels (FDR-adjusted P = 0.008) and amyloid-
PET levels (FDR-adjusted P = 0.001) at baseline (Fig. 2a,
b), suggesting the strongest association with brain amyl-
oid pathology. In addition, FERMT2 rs17125944 was de-
tected as associated with the altered CSF Aβ42 levels at
baseline and follow-up. The risk C allele carrier of
rs17125944 was associated with decreased CSF Aβ42
levels at baseline (FDR-adjusted P = 0.004), but these
changes over time were not clear from the longitudinal
analysis (Fig. 3a).
There were 9 other variants associated with brain
amyloidosis. FDR-adjusted P values are shown in Add-
itional file 1: Table S5. Among them, ADAM10
rs593742, BZRAP1-AS1 rs2526378, CELF1 rs3740688,
IGHV1-68 rs79452530, SLC24A4/RIN3 rs10498633, and
SLC24A4/RIN3 rs12590654 were associated with altered
CSF Aβ42 levels at baseline (Fig. 2a), while ADAMTS1
rs2830500, CLU rs11136000, and EPHA1 rs11771145
were associated with altered amyloid-PET levels at base-
line (Fig. 2b). Remarkably, there was no evidence for an
effect of these variants on CSF Aβ42 levels or amyloid-
PET levels from the longitudinal analysis.
Fig. 1 Association of the variants with gene expression in peripheral blood and brain regions. The significant associations between the variants
and the levels of gene expression in blood were identified from the ADNI database, and the significant associations in specific brain regions were
obtained from the Braineac dataset. FDR-adjusted P values with statistical significance are shown. Abbreviations: CRBL, cerebellar cortex; FCTX,
frontal cortex; HIPP, hippocampus; MEDU, medulla; OCTX, occipital cortex; PUTM, putamen; SNIG, substantia nigra; TCTX, temporal cortex; THAL,
thalamus; WHMT, intralobular white matter
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Fig. 2 Association of the variants with brain amyloidosis, tauopathy, and neurodegeneration (FDG-PET levels or MRI hippocampal volumes) at
baseline. We tested for significant associations of AD risk allele carrier status with brain amyloidosis, based on CSF Aβ42 or amyloid-PET data; the
associations with brain neurodegeneration, based on FDG-PET or MRI HVa data; and the associations with brain tauopathy, based on CSF pTau or
tau-PET data. a The minor allele carriers of ABCA7 rs3752246, BZRAP1-AS1 rs2526378, FERMT2 rs17125944, SLC24A4/RIN3 rs10498633, and SLC24A4/
RIN3 rs12590654 were significantly associated with decreased CSF Aβ42 levels, and ADAM10 rs593742, IGHV1-68 rs79452530, and CELF1 rs3740688
associated with increased CSF Aβ42 levels. b The minor allele carriers of ABCA7 rs3752246 were associated with increased amyloid-PET levels, and
ADAMTS1 rs2830500, CLU rs11136000, and EPHA1 rs11771145 associated with decreased levels of amyloid-PET. c The minor allele carriers of
BZRAP1-AS1 rs2526378 and HS3ST1 rs6448807 were associated with decreased FDG-PET levels. d The minor allele carriers of ECHDC3 rs11257242
were associated with increased MRI HVa levels. e The minor allele carriers of BIN1 rs744373 and BIN1 rs6733839 had lower CSF pTau levels, and
CD2AP rs9381563 and INPP5D rs10933431 had higher CSF pTau levels. f The minor allele carriers of BIN1 rs744373 and BIN1 rs7561528 had higher
tau-PET levels, and SLC24A4/RIN3 rs10498633 had lower tau-PET levels
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Association of variants with brain tauopathy
We examined the associations of AD risk allele carrier
status with brain tauopathy, based on CSF pTau or tau-
PET data at baseline and follow-up. Our results indicate
that BIN1 rs744373 was significantly associated with
CSF pTau levels (FDR-adjusted P = 0.004) and tau-PET
levels (FDR-adjusted P = 0.045) at baseline (Fig. 2e, f),
and thus, there is a strong association with brain tau
pathology. In addition, another two variants rs6733839
and rs7561528 in BIN1 were detected to be associated
with tau pathology. The minor allele carriers of
rs744373 and rs6733839 in BIN1 had lower CSF pTau
Fig. 3 Longitudinal effects of the variants on the change rates of brain amyloidosis, tauopathy, and neurodegeneration. a The risk C allele carrier
of FERMT2 rs17125944 was associated with decreased CSF Aβ42 levels at baseline, although these changes over time were not obvious from the
longitudinal analysis. b The longitudinal effect of PTK2B rs28834970 on the change rate of CSF pTau levels was significant. The minor allele
carriers of PTK2B rs28834970 exhibited faster rise in CSF pTau levels. c Longitudinal effects of CELF1 rs3740688 and PICALM rs3851179 on the
change rate of MRI HVa levels were significant. The minor allele carriers of CELF1 rs3740688 and PICALM rs3851179 exhibited slower decline in MRI
HVa levels. d Longitudinal effects of ADAMTS1 rs2830500, CD2AP rs9381563, and CD33 rs3865444 on the change rate of FDG-PET levels were
significant. The minor allele carriers of CD2AP rs9381563 exhibited faster decline in FDG-PET levels, and the minor allele carriers of ADAMTS1
rs2830500 and CD33 rs3865444 exhibited slower decline in FDG-PET levels. We analyzed the longitudinal effects of these variants on the change
rates of pathology using a linear mixed effect model. The shaded regions refer to 95% confidence intervals
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levels at baseline (Fig. 2e), and rs744373 and rs7561528
in BIN1 had higher tau-PET levels (Fig. 2f).
Furthermore, CD2AP rs9381563 and INPP5D
rs10933431 were discovered to be associated with al-
tered CSF pTau levels, and SLC24A4/RIN3 rs10498633
was associated with altered tau-PET levels at baseline
(Fig. 2e, f). Additional file 1: Table S5 lists the FDR-
corrected P results for these associations. Based on the
longitudinal follow-up data, although there was no asso-
ciation of PTK2B rs28834970 with brain tauopathy at
baseline, the longitudinal effect of this variant on the
change rate of CSF pTau levels was significant (FDR-ad-
justed P = 0.018). The minor allele carrier of PTK2B
rs28834970 was associated with the rapid growth rate of
CSF pTau levels (Fig. 3b; Additional file 1: Figure S3a).
Association of variants with brain neurodegeneration
We analyzed the associations of AD risk allele carrier
status with brain neurodegeneration, based on FDG-PET
or MRI HVa data at baseline and follow-up. The newly
discovered variants BZRAP1-AS1 rs2526378 and HS3ST1
rs6448807 were associated with altered FDG-PET levels
(FDR-adjusted P = 0.046 and P = 0.007, respectively;
Fig. 2c), and ECHDC3 rs11257242 associated with al-
tered MRI HVa levels (FDR-adjusted P = 0.045, Fig. 2d)
at baseline. Based on the longitudinal follow-up data, the
longitudinal effects of CELF1 rs3740688 and PICALM
rs3851179 on the change rate of MRI HVa levels were
significant, and the effects of ADAMTS1 rs2830500,
CD2AP rs9381563, and CD33 rs3865444 on the change
rate of FDG-PET levels were also significant, although
there was no association of these variants with brain
neurodegeneration at baseline. Figure 3c, d shows these
longitudinal associations (also in Additional file 1: Figure
S3b,c), and Additional file 1: Table S5 lists the FDR-
corrected P results.
It is worth noting that, according to our current set of
analyses, AD-associated genetic variants ADAMTS1
rs2830500, BZRAP1-AS1 rs2526378, and CELF1
rs3740688 might affect the mechanisms involved both in
brain amyloidosis and neurodegeneration, implying the
commonalities or convergence in function. AD-
associated genetic variants CD2AP rs9381563 might
affect the mechanisms involved both in brain tauopathy
and neurodegeneration, and SLC24A4/RIN3 rs10498633
in brain amyloidosis and tauopathy (Fig. 4).
Discussion
Although large GWAS has recently identified novel vari-
ants that are associated with altered AD risk, we have a
relatively poor understanding of their functional impact.
In this study, we comprehensively analyze possible func-
tional effects of the variants in top 30 non-APOE AD
risk genes, based on whether (1) these variants are asso-
ciated with altered expression levels and (2) the variants
are associated with brain amyloidosis, tauopathy, and
neurodegeneration.
Fig. 4 Role of variants in top 30 non-APOE AD risk genes in AD pathogenesis. Although most AD-associated genetic variants described to date
are located in intronic or noncoding regions, these variants still could affect the nearby gene expression and exert protective or disease-inducing
effects in AD-related amyloidosis, tauopathy, or neurodegeneration. Based on our analysis of all currently available data in ADNI, 11 variants were
associated with brain amyloidosis, 7 variants associated with brain tauopathy, and 8 variants associated with brain neurodegeneration. Among
them, variants in ADAMTS1, BZRAP1-AS1, and CELF1 affect the mechanisms involved both in brain amyloidosis and neurodegeneration, CD2AP in
brain tauopathy and neurodegeneration, and SLC24A4/RIN3 in brain amyloidosis and tauopathy, implying these genes might contribute to AD risk
via either common or distinct mechanisms
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Firstly, 27 variants were detected as associated with
the altered expression of 21 nearby genes in blood and
brain regions. Among them, variants in ABCA7,
ADAM10, ADAMTS1, BZRAP1-AS1, CASS4, CD2AP,
CD33, CELF1, CLU, HS3ST1, and PICALM were associ-
ated with the altered gene expressions in different brain
regions alone, and variants in BIN1, ECHDC3, EPHA1,
HLA-DRB1, NME8, and PTK2B were associated with the
altered gene expressions only in the blood, while only 6
variants in CR1, MS4A6A, SLC24A4/RIN3, and
ZCWPW1 affected these 4 nearby gene expressions both
in the blood and in the brain, which perhaps become
promising key biomarkers for AD diagnosis. Previous
studies have shown that the overlap of genomic variants
influencing transcript expression levels in both the hu-
man brain and blood is relatively low [24]. Of course,
the smaller sample sizes from human brain tissues might
be one possible reason for an underestimation of the
true level. Notably, although 6 variants are associated
with both brain and blood expression, the association
was not always in the same direction. For example, CR1
rs6701713 was associated with decreased expression in
blood but increased expression in specific brain regions.
The direction of association of the same variant in dif-
ferent brain regions was also different (Additional file 1:
Figure S2). Therefore, genetic variants may require tis-
sue-, cell-, region-, and disease-specific factors to exert
their influences on gene expression. In any case, the var-
iants associated with AD susceptibility are more likely to
affect the expression levels in a tissue-specific and
region-specific manner, and provide important regulat-
ing mechanisms of genetic variants in AD risk.
AD research has mainly focused in brain TCTX, HIPP,
and FCTX regions. Consistent with previous studies [12,
25–27], our study showed that AD risk variants in CR1,
CD33, CLU, and SLC24A4/RIN3 affect their gene ex-
pression levels in the above key regions for brain regula-
tory effects. Remarkably, the novel variant rs2526378 in
BZRAP1-AS1 was found to influence its expression levels
in TCTX/FCTX. Besides the changes in cortical regions,
some genetic variants were associated with the altered
expression in subcortical brain structures (THAL,
PUTM) or WHMT (Fig. 1). Because the degenerative
processes in these regions might contribute to cognitive
decline and are mechanistically important in AD [28–
30], more attention should be paid to these associations
in future research, which might become novel potential
treatment targets. In general, evaluating the potential as-
sociations using large-scale expression GWAS datasets
for multiple brain regions and peripheral blood in the
same individuals would provide more valuable
information.
Based on the baseline and longitudinal follow-up data,
we were able to confirm the previously reported
associations of genetic variants in ABCA7, CELF1, CLU,
EPHA1, and FREMT2 with brain amyloidosis as previ-
ously described [16, 20, 31]. The novel genome-wide
variants in ADAM10 (most important α-secretase in the
process of amyloid-β protein precursor (APP) cleavage)
[32, 33] and ADAMTS1 (within 665 kb of APP on
chromosome 21) [34] were also found to affect brain
amyloidosis. Additionally and to the best of our know-
ledge, we are the first to report the associations for novel
variants in IGHV1-68, BZRAP1-AS1, and SLC24A4/RIN3
with brain amyloidosis.
Previous studies have shown that BIN1 rs744373 was
associated with altered tau-PET and CSF pTau levels
[18, 35]. Our study supports the suggestion that other
variants in BIN1 are also significantly associated with tau
biomarkers. Similarly, we confirm the previously re-
ported association of INPP5D, CD2AP, and PTK2B with
brain tauopathy [19, 20, 36, 37]. Conversely, the relation-
ship between the variant in SLC24A4/RIN3 and tau
pathology is a new discovery. SLC24A4 CpG methylation
sites were found associated with Aβ burden and tau
pathology previously [38] and SLC24A4 also appeared to
take part in lipid metabolism [39] and brain glucose me-
tabolism [17].
As most of the earlier studies were cross-sectional ana-
lyses, a stage-specific association might occur for genetic
variants that influence the course of neurodegeneration
[17]. Using longitudinal follow-up data in our analysis, it
is possible to identify the effects of variants in CD2AP,
CD33, CELF1, and PICALM on the changes in brain me-
tabolism or atrophy over time, supporting the reported
associations of these genes with brain neurodegeneration
[17, 40–42]. However, the associations of variants in
ADAMTS1, ECHDC3, BZRAP1-AS1, and HS3ST1 with
neurodegeneration biomarkers at baseline are novel
findings of this research. Aligned with this, HS3ST1 was
reported as significantly associated with working mem-
ory in probable-MCI patients [43].
According to our results, variants in ADAMTS1, BZRAP1-
AS1, and CELF1 affect the mechanisms involved both in
brain amyloidosis and neurodegeneration, CD2AP in brain
tauopathy and neurodegeneration, and SLC24A4/RIN3 in
brain amyloidosis and tauopathy (Fig. 4), implying these
genes might contribute to AD risk via either common or dis-
tinct mechanisms. Previous studies have shown that ADAM
TS1, within 665 kb of APP on chromosome 21, has elevated
expression in Down’s syndrome and LOAD brain [34, 44]
and is a potential neuroprotective gene or neuroinflamma-
tory gene important to microglial response [45]. BZRAP1
(also known as TSPOAP1) is a subunit of the benzodiazepine
receptor complex in mitochondria and a marker of neuroin-
flammation. Previous studies have demonstrated that the
TSPO ligand can reverse Aβ accumulation and behavioral
impairment in transgenic mice [46]. Moreover, the CELF1
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variant has been shown to affect cognition and CSF Aβ42
levels by modifying expression [31, 47]. And the fly homolog
of CELF1, aret, also shows mediation of tau toxicity [48].
Much more research on the roles of these genes and how
they relate to each other is very important.
It is worth noting that, in our study, we place CSF and
PET imaging biomarkers all into analysis; that is because
the fundamental difference between the two should be
recognized. CSF biomarkers are measures of the concen-
trations of proteins in CSF from the lumbar sac that re-
flect the rates of both production (protein expression or
release/secretion from neurons or other brain cells) and
clearance (degradation or removal) at a given point in
time. While imaging measures, on the other hand, repre-
sent the magnitude of the neuropathologic load or damage
accumulated over time. Low CSF Aβ42 is therefore best
considered a biomarker of a pathologic state that is associ-
ated with amyloid plaque formation and not a measure of
amyloid plaque load as amyloid-PET is. Similarly, CSF
pTau is best considered a biomarker of a pathologic state
that is associated with PHF tau formation and not a meas-
ure of pathologic tau deposits as tau-PET is [15]. In
addition, FDG-PET was labeled as neurodegeneration bio-
markers in our current study, because our selection and
classification of biomarkers is based on the 2018 NIA-AA
research framework. However, a growing number of stud-
ies, including the recent article published by our team
[49], suggest FDG-PET as an independent biomarker for
Alzheimer’s biological diagnosis, because FDG hypometa-
bolism is a summation of multiple biological processes,
not just neuronal hypometabolism and neurodegenera-
tion. We sincerely hope more practitioners and academia
to deep study in this field to further improve the under-
standing of AD biomarkers.
Generally, the ultimate goal of understanding the gen-
etic architecture of AD is to enhance the understanding
of disease mechanisms. Based on the above A/T/N clas-
sification system, our identification of many risk genes
suggests their shared function in brain amyloidosis,
tauopathy, or neurodegeneration, which might provide
interesting targets for future functional follow-up and
biological interpretation.
Limitation
Our current study has limitations. Firstly, the subjects
with tau-PET data, especially the longitudinal tau-PET
data, are limited. Secondly, the follow-up CSF data are
limited because of the invasiveness of the procedure to
acquire samples. With the rapid development and wide
application of PET technology, future studies will valid-
ate our findings in a large, independent, longitudinal co-
hort with a greater number of individuals and time
points and with a longer follow-up time to provide more
statistically powerful results.
Conclusions
In summary, our current study provides new insights
into the variants in the top 30 non-APOE AD risk genes
associated with transcript expression levels and involved
in the pathological processes of brain amyloidosis, tauo-
pathy, and neurodegeneration. This evidence increases
the possibility that genetic variants might play functional
roles and suggest potential mechanisms in AD patho-
genesis. Further studies are needed to fully understand
their roles in AD process, and our research opens doors
to the investigation of novel targets for AD treatment.
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